Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435656 | 0.90 | HIF1A (0.50) | TRPV1HDAC1HIF1AEPAS1NAMPT | |
| SCHEMBL302457 | 0.83 | HDAC1 (0.63) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL2407989 | 0.82 | HDAC1 (0.62) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| Bromide SCHEMBL2409900 | 0.82 | HDAC1 (0.62) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| SCHEMBL2413630 | 0.81 | HDAC1 (0.66) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| SCHEMBL2416256 | 0.81 | HDAC1 (0.66) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| SCHEMBL2414034 | 0.80 | HDAC1 (0.51) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL3559032 | 0.80 | HDAC1 (0.62) | HDAC1NAMPTHDAC3HDAC4HDAC7 | |
| SCHEMBL2410013 | 0.80 | HDAC1 (0.67) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2413954 | 0.78 | HDAC1 (0.53) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437346-B9 | Benzamide derivatives useful as cell differentiation inducers | Bayer Pharma AG (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-1437346-B1 | Benzamide derivatives useful as cell differentiation inducers | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | TRPV1 1713/4885SIRT2 1558/4885SIRT1 1672/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | TRPV1 2342/4885SIRT2 1499/4885SIRT1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.